Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.52 and traded as low as $1.33. Spero Therapeutics shares last traded at $1.34, with a volume of 54,156 shares trading hands.
Analyst Ratings Changes
Several brokerages have recently commented on SPRO. Cantor Fitzgerald reissued an "overweight" rating on shares of Spero Therapeutics in a report on Thursday, April 4th. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Spero Therapeutics in a research report on Thursday, May 16th.
Read Our Latest Research Report on Spero Therapeutics
Spero Therapeutics Stock Down 2.2 %
The company has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $1.52. The stock has a market cap of $70.72 million, a P/E ratio of 3.07 and a beta of 0.64.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.17). The firm had revenue of $9.27 million during the quarter, compared to analysts' expectations of $16.80 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. As a group, sell-side analysts forecast that Spero Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Spero Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. ADAR1 Capital Management LLC bought a new position in shares of Spero Therapeutics during the fourth quarter valued at approximately $1,570,000. Acadian Asset Management LLC raised its holdings in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company's stock worth $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Spero Therapeutics in the 1st quarter worth about $31,000. Murchinson Ltd. boosted its stake in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company's stock valued at $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company's stock valued at $2,844,000 after buying an additional 9,675 shares during the period. Hedge funds and other institutional investors own 25.60% of the company's stock.
About Spero Therapeutics
(Get Free Report)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Articles
- Five stocks we like better than Spero Therapeutics
- What is Short Interest? How to Use It
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
→ Did Joe Biden just reveal his replacement? (From Paradigm Press) (Ad)
Should you invest $1,000 in Spero Therapeutics right now?
Before you consider Spero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.
While Spero Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Ten Starter Stocks For Beginners to Buy Now
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
